Saturday 17 October 2026
Export CLVSQ’s income statement to Excel — free account
Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
| Older periods | Dec '21 | Mar '22 | Jun '22 | Sep '22 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | 2 | 3 |
| 120.90% | 98.57% | 91.63% | 78.31% | ||
| (49.06%) | (51.66%) | (54.57%) | (58.94%) | ||
ROIC |
(71.85%) | (65.22%) | (73.03%) | 0.00% | |
Return on Tangible Assets |
(333.04%) | (370.81%) | (997.42%) | 39.31% | |
Average Days of Receivables |
65.93 | 68.73 | 48.32 | 53.38 | |
Free Cash Flow per Share |
(1.70) | (1.40) | (1.26) | (1.22) | |
Free Cash Flow |
(196.37) | (192.92) | (181.30) | (175.84) | |
Capital Expenditures |
(0.31) | (0.26) | (0.27) | (0.27) | |
| Other line items | |||||
Cash ROIC |
(40.64%) | (42.54%) | (48.04%) | (223.28%) | |
Accounts Receivable Turnover |
5.57 | 5.91 | 6.56 | 5.88 | |
Accounts Payable Turnover |
1.44 | 1.80 | 1.64 | 1.76 | |
Inventory Turnover |
1.75 | 2.11 | 2.00 | 2.58 | |
Average Days of Payables |
256.72 | 211.02 | 231.46 | 178.95 | |
Days of Inventory on Hand |
128.68 | 137.05 | 126.41 | 112.75 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
125.44% | 121.45% | 118.85% | 113.73% | |
Selling, General and Administrative Expense of Revenue |
86.32% | 88.08% | 90.78% | 94.37% | |
Share Based Compensation of Revenue |
17.11% | 19.35% | 18.60% | 18.02% | |
Interest Coverage |
(3.31) | (3.10) | (3.05) | (2.78) | |
Operating CF/Net income |
0.74 | 0.75 | 0.69 | 0.70 | |
Depreciation/Fixed assets |
1.67 | 1.76 | 1.88 | 2.05 | |
Capex/Depreciation |
(0.03) | (0.02) | (0.03) | (0.03) | |
Revenue per Share |
1.29 | 1.05 | 0.97 | 0.92 | |
Operating CF per Share |
(1.70) | (1.39) | (1.26) | (1.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates